{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:10:02Z","timestamp":1790125802701,"version":"4.0.1"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Patients with migraine often cycle through multiple nonspecific preventive medications due to poor tolerability and\/or inadequate efficacy leading to low adherence and increased disease burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy, tolerability, patient adherence, and patient satisfaction between erenumab and nonspecific oral migraine preventive medications (OMPMs) in patients with episodic migraine (EM) who had previously failed 1 or 2 preventive treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>The 12-month prospective, interventional, global, multicenter, active-controlled, randomized clinical trial comparing sustained benefit of 2 treatment paradigms (erenumab qm vs oral prophylactics) in adult episodic migraine patients (APPRAISE) trial was a 12-month open-label, multicenter, active-controlled, phase 4 randomized clinical trial conducted from May 15, 2019, to October 1, 2021. This pragmatic trial was conducted at 84 centers across 17 countries. Overall, participants 18 years or older with a 12-month or longer history of migraine, and 4 or more but fewer than 15 monthly migraine days (MMDs) were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Patients were randomized (2:1) to receive erenumab or OMPMs. Dose adjustment was permitted (label dependent).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end point was the proportion of patients completing 1 year of the initially assigned treatment and achieving a reduction of 50% or greater from baseline in MMDs at month 12. Secondary end points included the cumulative mean change from baseline in MMDs during the treatment period and the proportion of responders according to the Patients\u2019 Global Impression of Change (PGIC) scale at month 12 for patients taking the initially assigned treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 866 patients were screened, of whom 245 failed the screening and 621 completed the screening and baseline period. Of the 621 randomized patients (mean [SD] age, 41.3 [11.2] years; 545 female [87.8%]; 413 [66.5%] in the erenumab group; 208 [33.5%] in the OMPM group), 523 (84.2%) completed the treatment phase, and 98 (15.8%) discontinued the study. At month 12, significantly more patients assigned to erenumab vs OMPM achieved the primary end point (232 of 413 [56.2%] vs 35 of 208 [16.8%]; odds ratio [OR], 6.48; 95% CI, 4.28-9.82;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;.001). Compared with OMPMs, treatment with erenumab showed higher responder rate (314 of 413 [76.0%] vs 39 of 208 [18.8%]; OR, 13.75; 95% CI, 9.08-20.83;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;.001) on the PGIC scale (\u22655 at month 12). Significant reduction in cumulative average MMDs was reported with erenumab treatment vs OMPM treatment (\u22124.32 vs \u22122.65; treatment difference [SE]: \u22121.67 [0.35] days;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Substantially fewer patients in the erenumab arm compared with the OMPM arm switched medication (9 of 413 [2.2%] vs 72 of 208 [34.6%]) and discontinued treatment due to adverse events (12 of 408 [2.9%] vs 48 of 206 [23.3%]). No new safety signals were identified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Results of this randomized clinical trial demonstrated that earlier use of erenumab in patients with EM who failed 1 or 2 previous preventive treatments provided greater and sustained efficacy, safety, and adherence than continuous OMPM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03927144\">NCT03927144<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.0368","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T11:00:50Z","timestamp":1711364450000},"page":"461","source":"Crossref","is-referenced-by-count":38,"title":["Early Use of Erenumab vs Nonspecific Oral Migraine Preventives"],"prefix":"10.1001","volume":"81","author":[{"given":"Patricia","family":"Pozo-Rosich","sequence":"first","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institute of Research (VHIR), Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Spain"},{"name":"Headache Unit, Neurology Department, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dolezil","sequence":"additional","affiliation":[{"name":"Headache Center, Dado Medical sro, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Paemeleire","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Stepien","sequence":"additional","affiliation":[{"name":"Department of Neurology, Military Institute of Medicine-National Research Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Stude","sequence":"additional","affiliation":[{"name":"Neurological Practice Dr Stude, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefin","family":"Snellman","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Arkuszewski","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Stites","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Ritter","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Lopez Lopez","sequence":"additional","affiliation":[{"name":"Former employee of Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Maca","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Ferraris","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gil-Gouveia","sequence":"additional","affiliation":[{"name":"Hospital da Luz Headache Center, Neurology Department, Hospital da Luz, Lisboa, Portugal"},{"name":"Center for Interdisciplinary Research in Health, Universidade Cat\u00f3lica Portuguesa, Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"noi240013r1","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","article-title":"Adherence to oral migraine-preventive medications among patients with chronic migraine.","volume":"35","author":"Hepp","year":"2015","journal-title":"Cephalalgia"},{"issue":"22","key":"noi240013r2","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine.","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"noi240013r3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"issue":"9","key":"noi240013r4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of Galcanezumab for the Prevention of Episodic Migraine: the EVOLVE-1 randomized clinical trial.","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"issue":"8","key":"noi240013r5","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"issue":"24","key":"noi240013r6","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study.","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"issue":"19","key":"noi240013r7","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial.","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"issue":"22","key":"noi240013r8","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine.","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"noi240013r9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1).","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"issue":"13","key":"noi240013r10","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"noi240013r11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention: 2022 update.","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"},{"issue":"1","key":"noi240013r12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.2019.59.issue-1","article-title":"The American Headache Society position statement on integrating new migraine treatments into clinical practice.","volume":"59","author":"American Headache Society","year":"2019","journal-title":"Headache"},{"issue":"1","key":"noi240013r16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","article-title":"Systematic review of migraine prophylaxis adherence and persistence.","volume":"20","author":"Hepp","year":"2014","journal-title":"J Manag Care Pharm"},{"issue":"5","key":"noi240013r17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","article-title":"Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis.","volume":"37","author":"Hepp","year":"2017","journal-title":"Cephalalgia"},{"issue":"1","key":"noi240013r18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.18553\/jmcp.2018.18058","article-title":"Cycling through migraine preventive treatments: implications for all-cause total direct costs and disease-specific costs.","volume":"25","author":"Ford","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"noi240013r19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.2013.53.issue-4","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II).","volume":"53","author":"Blumenfeld","year":"2013","journal-title":"Headache"},{"issue":"3","key":"noi240013r20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/head.v61.3","article-title":"Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: results from the Assessment of Tolerability and Effectiveness in Migraine Patients using Preventive Treatment (ATTAIN) study.","volume":"61","author":"Kawata","year":"2021","journal-title":"Headache"},{"issue":"5","key":"noi240013r21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"18","author":"Collaborators","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"noi240013r22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019.","volume":"21","author":"Steiner","year":"2020","journal-title":"J Headache Pain"},{"issue":"5","key":"noi240013r23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy.","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"noi240013r24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/0333102414552532","article-title":"The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) study methods and baseline results.","volume":"35","author":"Adams","year":"2015","journal-title":"Cephalalgia"},{"issue":"3","key":"noi240013r25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","article-title":"Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS).","volume":"31","author":"Blumenfeld","year":"2011","journal-title":"Cephalalgia"},{"issue":"1","key":"noi240013r26","doi-asserted-by":"publisher","first-page":"8286","DOI":"10.1038\/s41598-021-87352-2","article-title":"Impact of monthly headache days on anxiety, depression, and disability in migraine patients: results from the Spanish Atlas.","volume":"11","author":"Irimia","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"noi240013r27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","article-title":"My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed.","volume":"19","author":"Martelletti","year":"2018","journal-title":"J Headache Pain"},{"issue":"2","key":"noi240013r28","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s40122-021-00331-3","article-title":"Burden of migraine in patients with preventive treatment failure attending european headache specialist centers: real-world evidence from the BECOME study.","volume":"10","author":"Pozo-Rosich","year":"2021","journal-title":"Pain Ther"},{"issue":"5","key":"noi240013r29","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.v28.5","article-title":"Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial.","volume":"28","author":"Ashina","year":"2021","journal-title":"Eur J Neurol"},{"issue":"6","key":"noi240013r30","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a phase 3 randomized trial of erenumab for episodic migraine.","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"issue":"10161","key":"noi240013r31","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom 2-to-4 previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"noi240013r32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.v61.2","article-title":"Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.","volume":"61","author":"Barbanti","year":"2021","journal-title":"Headache"},{"issue":"10","key":"noi240013r33","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","article-title":"The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study.","volume":"268","author":"Torres-Ferr\u00fas","year":"2021","journal-title":"J Neurol"},{"issue":"1","key":"noi240013r34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-020-01171-w","article-title":"Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region.","volume":"21","author":"Ornello","year":"2020","journal-title":"J Headache Pain"},{"issue":"1","key":"noi240013r35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","article-title":"Erenumab in highly therapy-refractory migraine patients: first German real-world evidence.","volume":"21","author":"Scheffler","year":"2020","journal-title":"J Headache Pain"},{"issue":"10","key":"noi240013r36","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1111\/head.v60.10","article-title":"Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study.","volume":"60","author":"Alex","year":"2020","journal-title":"Headache"},{"issue":"2","key":"noi240013r37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","article-title":"Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.","volume":"42","author":"Reuter","year":"2022","journal-title":"Cephalalgia"},{"issue":"1","key":"noi240013r38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders 3rd edition.","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"12","key":"noi240013r39","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1001\/jama.282.12.1157","article-title":"Capturing the patient\u2019s view of change as a clinical outcome measure.","volume":"282","author":"Fischer","year":"1999","journal-title":"JAMA"},{"issue":"9","key":"noi240013r40","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/13696998.2019.1636051","article-title":"Real-world healthcare resource utilization related to migraine treatment failure: a panel-based chart review in France, Germany, Italy, and Spain.","volume":"22","author":"Vo","year":"2019","journal-title":"J Med Econ"},{"issue":"5","key":"noi240013r41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","article-title":"Cost of healthcare for patients with migraine in 5 European countries: results from the International Burden of Migraine Study (IBMS).","volume":"13","author":"Bloudek","year":"2012","journal-title":"J Headache Pain"},{"issue":"1","key":"noi240013r42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-019-1068-y","article-title":"Cost of chronic and episodic migraine patients in continuous treatment for 2 years in a tertiary level headache Centre.","volume":"20","author":"Negro","year":"2019","journal-title":"J Headache Pain"},{"issue":"4","key":"noi240013r43","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/hed.2009.49.issue-4","article-title":"Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.","volume":"49","author":"Munakata","year":"2009","journal-title":"Headache"},{"issue":"5","key":"noi240013r44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/ene.2012.19.issue-5","article-title":"The cost of headache disorders in Europe: the Eurolight project.","volume":"19","author":"Linde","year":"2012","journal-title":"Eur J Neurol"},{"issue":"1","key":"noi240013r45","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s10194-023-01682-2","article-title":"Impact of a reimbursement policy change on treatment with erenumab in migraine\u2014a real-world experience from Germany.","volume":"24","author":"Hong","year":"2023","journal-title":"J Headache Pain"},{"issue":"10","key":"noi240013r46","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.jval.2021.04.1281","article-title":"Social impact of prophylactic migraine treatments in Germany: a state-transition and open cohort approach.","volume":"24","author":"Seddik","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"noi240013r47","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12883-023-03302-7","article-title":"Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine.","volume":"23","author":"Siersb\u00e6k","year":"2023","journal-title":"BMC Neurol"},{"key":"noi240013r48","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/PROM","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization.","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"issue":"1","key":"noi240013r49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s10194-021-01366-9","article-title":"In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention: a real-world evidence study.","volume":"22","author":"Alpuente","year":"2021","journal-title":"J Headache Pain"},{"key":"noi240013r50","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/pharmtox.2019.59.issue-1","article-title":"The placebo effect in pain therapies.","volume":"59","author":"Colloca","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"noi240013r51","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s10194-023-01587-0","article-title":"The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression.","volume":"24","author":"Tepper","year":"2023","journal-title":"J Headache Pain"},{"issue":"3","key":"noi240013r52","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s004150050560","article-title":"Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos.","volume":"247","author":"de Craen","year":"2000","journal-title":"J Neurol"},{"key":"noi240013r53","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/978-3-030-35362-9","article-title":"Placebos and the Placebo Effect in Drug Trials.","volume":"260","author":"Enck","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"noi240013r13","unstructured":"Italian Medicines Agency. Attivazione web e pubblicazione schede di monitoraggio\u2014registro AIMOVIG. Accessed February 20, 2024. https:\/\/www.aifa.gov.it\/en\/-\/attivazione-web-e-pubblicazione-schede-di-monitoraggio-registro-aimovig"},{"key":"noi240013r14","unstructured":"National Institute for Health and Care Excellence. Erenumab for preventing migraine. Accessed February 20, 2024. https:\/\/www.nice.org.uk\/guidance\/ta682\/chapter\/1-Recommendations"},{"key":"noi240013r15","unstructured":"DGN. DGN Guidelines home page. Accessed February 20, 2024. https:\/\/dgn.org\/leitlinien\/"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2816800\/jamaneurology_pozorosich_2024_oi_240013_1714578866.98036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:02:09Z","timestamp":1715598129000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2816800"}},"subtitle":["The APPRAISE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.0368","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}